We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMGWP
RNS Number : 6325T
GW Pharmaceuticals PLC
07 October 2014
GW Pharmaceuticals PLC ("GW Pharmaceuticals")
ADDITIONAL LISTING
Porton Down, UK, 7 October 2014: GW Pharmaceuticals (AIM: GWP) hereby provides notification that application has today been made to the London Stock Exchange for admission to trading on AIM of 13,601 new ordinary shares of 0.1p each ("New Ordinary Shares").
The New Ordinary Shares are being issued pursuant to a subscription agreement connected to the acquisition of certain IP rights.
It is expected that such admission will become effective on 13 October 2014 and following admission to trading of the New Ordinary Shares 236,685,496 ordinary shares of 0.1 pence each will be in issue.
For further information, please contact:
GW Pharmaceuticals PLC +44 (0)1980 557 000
Adam George, Company Secretary
Peel Hunt LLP (Nominated Adviser)
James Steel/Oliver Jackson +44 (0) 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISGIBDGDSGBGSR
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
